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Abstract
Background: The Infection and Treatment Method (ITM) of vaccination is the only immunization procedure currently
available to protect cattle against East Coast fever (ECF), a tick-transmitted disease responsible for losses of several
hundreds of millions of dollars per year in sub-Saharan Africa. The vaccine comprises a homogenized preparation of
infected ticks packaged in straws and stored in liquid nitrogen. The current manufacturing protocol results in straws
containing 30–40 doses (ILRI 0804), which is impractical for immunizing small herds as found in dairy and smallholder
farming systems. The ILRI 0804 SD stabilate was prepared as a 1:5 dilution of the parent stabilate, with the aim of
producing vaccine stabilate straws containing between four to eight doses and thus suitable for smallholder
farming systems. Infectivity of the diluted stabilate was assessed and the protective efficacy of the diluted
stabilate was determined by performing experimental and field immunizations.
Results: Two groups of six cattle were inoculated with 1 ml of the diluted stabilate at 1:20 (equivalent to
the recommended field dose for ILRI 0804, assuming no loss of sporozoite viability during thawing and refreezing)
and 1:14 (assuming 30–35% loss of sporozoite viability). Schizonts were detected in all 12 animals, showing viability
of sporozoites. Ten animals from the infectivity study and two control animals not previously exposed to T.
parva were challenged with the parental ILRI 0804 stabilate. The results show that the two control animals
displayed severe ECF reactions and were treated 14 days after challenge. Of the previously infected animals,
only one underwent a severe reaction following challenge, a result in accord with the challenge experiments
performed previously with the parent stabilate [Ticks Tick-Borne Dis 7:306-314, 2016]. The animal that displayed a
severe reaction had no detectable schizonts and did not seroconvert following the initial inoculation with ILRI 0804 SD.
In addition, 62 animals immunized under field conditions showed a mean seroconversion rate of 82%.
Conclusion: The results presented in this article demonstrate that it is possible to prepare straws suitable for use in
smallholder herds by thawing, diluting and refreezing already packaged vaccine.
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Background
East Coast fever (ECF) is an economically important dis-
ease of cattle in both smallholder and pastoralist systems
in 11 countries in sub-Saharan Africa. It is estimated
that the disease is responsible for economic losses of
over US$300 million per year [7, 10], with at least 40
million cattle in the region exposed to the disease [8].
ECF is caused by the tick-transmitted apicomplexan
parasite, Theileria parva, and is characterised by a severe
lymphoproliferative disorder. Mortality and morbidity
rates in susceptible animals can approach 90% [2].
The only currently available method of immunization
against ECF is known as the Infection and Treatment
Method (ITM). The vaccine consists of a homogenized
and partially purified preparation of infected ticks, which
is administered simultaneously with long-acting oxyteta-
cycline. The oxytetracycline serves to prevent the devel-
opment of severe clinical disease from the otherwise
lethal dose of sporozoites. Lynen et al. [5] demonstrated
that ITM is the most effective method for ECF control
in Tanzania’s smallholder dairy sector. The vaccine is ex-
pensive, costing at least US$7 per animal, although this
is considerably less than the cost of treatment of US$40
per animal [5].
The most commonly used version of the ITM vaccine
is the Muguga cocktail, which is a mixture of stabilates
from three different T. parva isolates [14] and comprises
multiple parasite types as demonstrated by genomic ana-
lysis of mini- and micro-satellites and polymorphic anti-
gens [1, 12]. The recent commercial-scale productions
of the ITM Muguga cocktail vaccine resulted in vaccine
stabilate packaged at between 30 and 40 doses per 0.5 ml
straw [13]. The straws are stored in liquid nitrogen to
maintain sporozoite viability. These factors present prac-
tical difficulties for some livestock owners, such as
smallholder farmers with small numbers of cattle to be
vaccinated.
One potential approach to overcome this issue is to
thaw, dilute, repackage and refreeze the stabilate from
already dispensed straws. It does, however, rely on there
being minimal loss of sporozoite viability or of key anti-
genic components of the vaccine during the repackaging
process. In a previous study, Mbao et al. [6] showed that
sporozoites from a single stabilate showed 33–35%
loss of in vitro infectivity following thawing and re-
freezing. However, no dilution step or in vivo analysis
was reported.
This paper describes a method for thawing, diluting,
repackaging and refreezing the ITM Muguga cocktail
vaccine stabilate to retain sporozoite infectivity and anti-
genicity, as judged by seroconversion and protection
from challenge with the parent stabilate. The paper also
presents results from the field immunizations where the
newly diluted vaccine was tested and shown to be
immunogenic, with seroconversion detectable in 82% of
vaccinated animals.
Results
The parent ILRI 0804 stabilate is recommended for use
at a dilution of 1:100, which yields about 40 doses per
straw. The diluted and repackaged stabilate described
here (ILRI 0804 SD stabilate) was prepared as a 1:5 dilu-
tion of the parent stabilate, with the aim of producing
vaccine stabilate straws containing between four to eight
doses and thus suitable for smallholder farming systems.
Determining the infectivity of the ILRI 0804 SD vaccine
stabilate
In order to assess the infectivity of the diluted stabilate
two groups of six cattle were inoculated with 1 ml of the
stabilate, diluted either 1:20 or 1:14. The dilution of 1:20
represents a dose equivalent to the recommended field
dose of ILRI 0804 (1:100) assuming no loss of viability,
whereas the 1:14 dilution assumes there was about a
33–35% loss of infective sporozoites during repackaging
[6]. The cattle were inoculated without simultaneous ad-
ministration of oxytetracycline, in line with previous
procedures [13]. The results (Table 1) showed that schiz-
onts were detected in nine of the 12 animals, demon-
strating that the stabilate contained viable, infective
sporozoites. This was supported by the results of the
serological testing, which showed that all but one of the
animals, including two of those in which schizonts were
not detected, seroconverted within 28 days of inocula-
tion. There was no apparent correlation of the clinical
outcome with dose, as each of the dilution groups had
two animals showing moderate reactions. Similarly, two
of the three animals in which there was no apparent re-
action had received the 1:14 stabilate dilution.
Determining the protective efficacy of ILRI 0804 SD by
stabilate challenge
To determine whether the thawing and refreezing process re-
sulted in loss of minor key antigenic components, the in-
fected animals were challenged with the parent stabilate, in
the expectation that any loss of major antigenic types would
result in parasite breakthrough. This approach would also
confirm if the animals had received a protective dose of spo-
rozoites. Ten animals had survived untreated from the infect-
ivity experiment, as one animal (BF053) died and another
(BF055) was euthanized 36 and 24 days after inoculation, re-
spectively, due to causes unrelated to ECF. All 10 animals
and two control animals not previously exposed to T. parva
were challenged with the parental ILRI 0804 stabilate.
The results (Table 2) show that the two control animals
displayed severe ECF reactions and were treated 14 days
after challenge. Of the previously infected animals, only
one underwent a severe reaction following challenge, a
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result in accord with the challenge experiments performed
previously with the parent stabilate [13]. The animal that
displayed a severe reaction (BF061) had no detectable
schizonts and did not seroconvert following the initial in-
oculation with ILRI 0804 SD. It would appear that this
animal received a sub-optimal dose of viable sporozoites,
although the reasons for this are not clear. In comparing
the clinical outcomes of the two groups, it was noted that
four of the animals in each group underwent mild reac-
tions, indicating that there was very little difference in the
protection afforded by the two dilutions. We were also
able to compare difference in the mean time to and mean
duration of parasitosis between the two groups. The ana-
lysis showed there was no statistically significant differ-
ence (p = 0.115–0.147 and 0.685–0.736, respectively).
Performance of the ILRI 0804 SD vaccine stabilate in a
field immunization in Tanzania
Field immunizations were undertaken in various loca-
tions in northern Tanzania to assess the performance of
Table 1 Clinical and parasitological responses in cattle inoculated with the ILRI 0804 SD vaccine stabilate at a dilution of 1:14 or 1:20
Animal Days to fever Duration of fever (d) Days to schizonts Duration of schizonts (d) Days to piroplasms ECF reaction Day of seroconv.
Group 1. Immunizing Dose - 1:14
BF 051 nda nd 12 2 nd mild 21
BF 053 14 6 12 8 15 mod.b 21
BF 056 nd nd 12 2 nd mild 21
BF 061 nd nd nd nd nd nrc nd
BF 066 nd nd nd nd nd nr 28
BF 069 13 1 10 5 15 mod. 21
Group 2. Immunizing Dose - 1:20
BF 049 nd nd 8 1 nd mild 21
BF 052 nd nd nd nd nd nr 28
BF 055 13 4 9 13 15 mod. 21
BF 060 11 7 9 6 14 mild 21
BF 065 nd nd 11 4 nd mild 21
BF 068 14 8 9 9 15 mod. 21
and = not detected
bmod. = moderate
cnr = no apparent reaction
Table 2 Clinical and parasitological responses in cattle challenged with ILRI 0804 vaccine stabilate
Animal Days to fever Duration of fever (d) Days to schizonts Duration of schizonts (d) Days to piroplasm ECF reaction
Group 1 Immunizing Dose 1:14
BF 051 12 2 8 8 nda mild
BF 056 nd nd 9 1 nd mild
BF 061 11 10 11 8 15 severe
BF 066 nd nd 8 2 nd mild
BF 069 nd nd 8 1 nd mild
Group 2 Immunizing Dose 1:20
BF 049 nd nd 13 3 nd mild
BF 052 8 7 8 10 15 modb.
BF 060 nd nd 11 5 nd mild
BF 065 nd nd nd nd nd mild
BF 068 nd nd 13 2 nd mild
Control
BF 045 9 7 8 10 13 severe
BF 071 8 10 8 11 13 severe
and = not detected
bmod. = moderate
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the ILRI 0804 SD stabilate under field conditions. The
stabilate was administered at a dilution (1:10), which
would yield approximately four doses per straw and thus
be suitable for small herds. The stabilate was adminis-
tered simultaneously with oxytetracycline to mimic the
expected field use of the vaccine.
Of the 63 calves included in the analysis, only two
showed clinical signs after vaccination. One calf died 26
days after immunization from complications not neces-
sarily related to ECF, while a second calf was treated
with buparvaquone (Butalex, Coopers Animal Health,
Nairobi) when it showed inappetence 17 days after
immunization, and recovered immediately. The serocon-
version rates following immunization varied from 75 to
87% among farms, with an overall mean rate of 82%.
The results indicate that the ILRI 0804 SD stabilate is
safe and immunogenic when used at 1:10 (four doses
per straw). As no control (unvaccinated) groups were in-
cluded in this study, it is not possible to conclude defini-
tively that the vaccine was protective but two ECF cases
were recorded in non-vaccinated animals on one farm
during the observation period.
Discussion
The current ITM Muguga Cocktail (ILRI 0804) is pack-
aged and stored as 30–40 doses which is impractical for
smallholder farmers with fewer cattle. Therefore, the
ILRI 0804 SD stabilate was prepared as a 1:5 dilution of
the parent stabilate after thawing and refreezing already
packaged straws, with the aim of producing vaccine sta-
bilate straws containing between four to eight doses and
thus suitable for smallholder farming systems. The possi-
bility that the thawing and refreezing process during the
preparation of diluted stabilate results in unacceptable
loss of sporozoite viability was addressed in an infectivity
assay, with the results showing that the stabilate was suf-
ficiently viable to induce parasitosis and antibody re-
sponses when administered at a practically useful
dilution. The subsequent challenge experiment involving
a lethal inoculation of the parent stabilate demonstrated
that the ILRI 0804 SD stabilate was protective and that
there was no observable loss in key antigenic compo-
nents from the Muguga cocktail stabilate. The results of
the field immunization reinforced these results, with
high seroconversion rates and minimal clinical reactions
after immunization. If used as in the field trial at a dilu-
tion of 1:10, the resultant pack size of four doses per
straw is immensely attractive for use in the smallholder
dairy sector. The resources required for close monitor-
ing and clinical follow-up of the animals in the field for
an extended period were beyond the scope of the
current study and no definitive conclusions regarding
field protection could be drawn. However, the observa-
tion that over 1 million doses of the ILRI 0804 batch of
vaccine have been used with no confirmed reports of
vaccine failure when administered correctly suggests that
the ILRI 0804 SD stabilate will be safe and effective
under field conditions when used at a dilution which
should be commercially attractive in the field.
An alternative approach to producing a vaccine stabi-
late at 5–10 doses per straw is to prepare a more dilute
stabilate for initial packaging. This has the disadvantages
of requiring a greater liquid nitrogen storage capacity, a
reliable estimate of how much of the bulk vaccine stabi-
late should be packaged at the more dilute preparation
and accurate prediction of the potency of each vaccine
batch. Although the approach described here may result
in some loss of sporozoite viability, it does allow the
preparation of diluted straws according to demand and
reduction in the amount of space required for storage in
liquid nitrogen. A further improvement to this approach
would be to store the vaccine stabilate as a bulk prepar-
ation [11] and prepare appropriately diluted stabilate
straws when needed.
Conclusion
In summary, we have shown that the thawing, dilut-
ing and re-freezing of an already dispensed prepar-
ation of the ITM Muguga cocktail vaccine stabilate
results in a viable preparation useful for smallholder
herds. Although there will be slightly increased costs
associated with the production of the diluted and
repackaged stabilate, this should be offset by de-
creased wastage of thawed but unused vaccine associ-
ated with use of the 40-dose straws and a perceived
willingness of smallholder farmers to pay more to
protect highly valuable animals.
Methods
Animals
All animal procedures used in the infectivity and chal-
lenge trials were approved by ILRI’s Institute Animal
Care and Use Committee (IACUC File numbers 2011.02
and 2011.06). The animals used in this study were Bos
indicus (Boran) cattle aged between from 9 and 12
months and were brought from the ILRI Kapiti farm
where they were maintained under a strict acaricide re-
gime. Before use, all cattle were screened by enzyme-
linked immunosorbent assay (ELISA) to detect prior
exposure to T. parva, Theileria mutans, Babesia bige-
mina, and Anaplasma marginale [3, 4, 9, 15] and Bovine
Leukosis Virus (IDEXX Leukosis Serum × 2 Ab Test,
IDEXX, Westbrook, Me, USA). Giemsa-stained blood
smears were examined for haemoparasites and Ehrlichia
spp. Only animals that were negative in all assays were
included in the experiments.
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Vaccine stabilate
The Muguga cocktail vaccine stabilate ILRI 0804 has
been previously described [13]. One hundred, 0.5 ml
straws of the stabilate were selected at random and used
to produce the diluted and repackaged straws.
Thawing, diluting and repackaging stabilates
The straws were placed on a steel tray floating in a 37 °C
water bath for 2–3 min. The thawed straws were pierced
with a fine needle at the sealed end to allow the stabilate
to flow into a flask on ice with stirring. A total stabilate
volume of 45 ml was recovered. To achieve a 1:5 dilu-
tion, 180 ml of cryoprotectant medium (Eagle’s minimal
essential medium, with 3.5% bovine serum albumin and
7.5% glycerol) was added slowly for 5 min at 1 drop per
second, followed by a gradual increase in the flow rate
to 2 drops per second for 5 min. The remaining medium
was added as a slow trickle. The newly diluted stabilate,
named ILRI 0804 SD, was mixed for a further 5 min be-
fore being dispensed using a vacuum manifold into 0.5
ml straws sealed at one end and labelled ECF MC ILRI
0804 SD. The entire procedure from thawing to filling
was completed in 65min. The newly filled straws were
placed into plastic goblets on ice and left at − 80 °C over-
night. The following day they were transferred into li-
quid nitrogen for long-term storage.
Infectivity trial of the ILRI 0804 SD stabilate
The viability of the diluted and refrozen stabilate was de-
termined in an infectivity trial using 12 animals placed
randomly into two groups of six. The groups received 1
ml of either a 1:14 or a 1:20 dilution of the ILRI 0804
SD, delivered by subcutaneous inoculation below and
anterior to the right parotid lymph node (without oxy-
tetracycline). The animals were monitored for clinical
and parasitological reactions as described previously
[13]. Seroconversion to T. parva was assessed with the
indirect ELISA [4] on sera collected at seven-day inter-
vals from the day of inoculation. A percent positivity
value of 19 or greater was considered positive.
Challenge trial
Fifty days after inoculation, the surviving animals from
the infectivity trial were challenged with a lethal dose of
the parent stabilate ILRI 0804 (1 ml undiluted) adminis-
tered as above. Two control animals not previously ex-
posed to T. parva were included to ensure that the
challenge dose and procedure was appropriate. The ani-
mals were monitored for clinical and parasitological re-
actions as before.
Field immunizations
Field immunizations were undertaken in seven locations
in northern Tanzania, six smallholder dairy farms in
peri-urban Arusha/Arumeru District and one commer-
cial Boran farm, between November 2011 and November
2012. The calves at the smallholder dairy farms were
mainly Bos taurus (Jersey or Friesian) aged 1–4 months
and the commercial farm had Bos indicus Boran calves,
aged 1–4 months. The animals were immunized by in-
oculation with 1 ml of a 1:10 dilution of the ILRI 0804
SD stabilate as above, together with 30% long acting
oxytetracycline administered intramuscularly. The ani-
mals were monitored for indications of ECF following
vaccination. Serum samples were collected from the day
of immunization and between 32 and 50 days following
immunization and were assessed for anti-T. parva anti-
bodies as above. Following removal of some samples due
to pre-immunization positivity, the sera from 63 cattle
were analysed.
Statistical analysis
Differences in clinical outcomes (time to and duration of
parasitosis) between the groups in the challenge trial
were assessed using a random permutation t-test equiva-
lent run 10 times to establish a range in the R software
version 3.0.2 (R Core Team, 2013).
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